CA2570450A1 - Pharmaceutically elegant, topical anhydrous aerosol foam - Google Patents
Pharmaceutically elegant, topical anhydrous aerosol foam Download PDFInfo
- Publication number
- CA2570450A1 CA2570450A1 CA002570450A CA2570450A CA2570450A1 CA 2570450 A1 CA2570450 A1 CA 2570450A1 CA 002570450 A CA002570450 A CA 002570450A CA 2570450 A CA2570450 A CA 2570450A CA 2570450 A1 CA2570450 A1 CA 2570450A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- actives
- combinations
- sorbitan
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/31—Anhydrous
Abstract
A topical pharmaceutical aerosol foam containing liquid silicones to enhance cosmetic elegance. Although liquid silicones are inherent defoamers, a high quality, stable foam is produced.
Description
TITLE: PHARMACEUTICALLY ELEGANT, TOPICAL ANHYDROUS
AEROSOL FOAM
FIELD OF THE INVENTION
This invention relates to topical pharmaceutical compositions.
BACKGROUND OF THE INVENTION
Topical pharmaceutical compositions are, of course, well known. They can be used as water proofing agents, sunscreens, skin conditioning agents, lip balms, wound dressings, hair pomades, etc. Regardless of the specific use, common to pharmaceutically satisfactory topical actives are that they must stay on the skin for a sufficient period of time to allow the active to perform; they must not irritate the skin; and, they must be perceived by the patient as pharmaceutically elegant or the patient will simply not use them. By "pharmaceutically elegant", as those skilled in the art know, one means the skin feel to the patient is good. It must not be too watery or too greasy. Some say it relates to the creaminess or lubricity properties as well as 'moisture retaining' properties.
There is a continual need for improvements in topical carrier systems, particularly for those that are lipophilic in nature, most of which are perceived by consumers as too waxy or too greasy when smeared on the skin. This invention relates to this need.
While aerosol delivery lipophilic systems have been used for topicals before, a problem with typical aerosol systems is to develop one that does not feel greasy and which is cosmetically superior. Known non-aerosol compositions which provide a nongreasy feel in topicals can include liquid silicones such as cyclomethicone, hexamethyldisiloxane, and dimethiconol. However, such liquid silicones are recognized in the art as defoaming agents. Defoaming agents are not something that one would want to add to a topical aerosol composition where foaming is an essential part of the delivery system since they act to defoam. Surprisingly, it has been found, however, that in the current invention, a topical aerosol foam composition has been created that does contain a large quantity of liquid silicones and yet it unexpectedly produces quality foam.
This invention offers a number of other benefits to the user which are also desirable objectives. The drug delivery system in the form of foam facilitates a novel, yet efficient mode of topical drug delivery system. It also facilitates continuous product output thereby adding ease of application. When dispensed in small quantity, the drug delivery system in the form of a foam can also cover a larger surface area of application while also facilitating better product application in areas where conventional topical products cannot be as effective. The drug delivery system in the form of foam also facilitates the use of a lower dosage which can minimize adverse reactions. The other crucial benefit is that this foam form of delivery system is devoid of any contact with air, light, or any other form of contamination as this is a completely sealed system throughout the life of the product.
Thus, light and oxidation prone topical actives can be preserved effectively in the aerosol system. The anhydrous system of the carrier further extends the preservation of topical actives that are otherwise easily degraded by presence of a water base.
Accordingly, it is a primary object of the present invention to prepare a topical application or pharmaceutical composition which is of widespread applicability (i.e. useful with many drug actives) and which is at the same time perceived by the user as pharmaceutically elegant.
Another objective of the present invention is to achieve the primary object with a composition especially adapted for lipophilic compounds and which can provide effective delivery in the form of a foam.
A yet further objective is to provide a method of preparation of a topical application or pharmaceutical composition in the form of a foam that achieves each of the above objectives or attributes.
The method and manner of achieving each of the above objectives as well as other objectives of the invention, will become apparent from the following detailed description of the invention.
SUMMARY OF THE INVENTION
A topical pharmaceutical aerosol foam composition containing a lipophilic compound, a liquid silicone, a foaming agent, a propellant and a topical pharmaceutical active. The composition may also contain rheology modifiers that serve as foam stabilizers. The composition exhibits excellent emollient and rub-in characteristics. The composition when expelled from an aerosolized container produces surprisingly good.
AEROSOL FOAM
FIELD OF THE INVENTION
This invention relates to topical pharmaceutical compositions.
BACKGROUND OF THE INVENTION
Topical pharmaceutical compositions are, of course, well known. They can be used as water proofing agents, sunscreens, skin conditioning agents, lip balms, wound dressings, hair pomades, etc. Regardless of the specific use, common to pharmaceutically satisfactory topical actives are that they must stay on the skin for a sufficient period of time to allow the active to perform; they must not irritate the skin; and, they must be perceived by the patient as pharmaceutically elegant or the patient will simply not use them. By "pharmaceutically elegant", as those skilled in the art know, one means the skin feel to the patient is good. It must not be too watery or too greasy. Some say it relates to the creaminess or lubricity properties as well as 'moisture retaining' properties.
There is a continual need for improvements in topical carrier systems, particularly for those that are lipophilic in nature, most of which are perceived by consumers as too waxy or too greasy when smeared on the skin. This invention relates to this need.
While aerosol delivery lipophilic systems have been used for topicals before, a problem with typical aerosol systems is to develop one that does not feel greasy and which is cosmetically superior. Known non-aerosol compositions which provide a nongreasy feel in topicals can include liquid silicones such as cyclomethicone, hexamethyldisiloxane, and dimethiconol. However, such liquid silicones are recognized in the art as defoaming agents. Defoaming agents are not something that one would want to add to a topical aerosol composition where foaming is an essential part of the delivery system since they act to defoam. Surprisingly, it has been found, however, that in the current invention, a topical aerosol foam composition has been created that does contain a large quantity of liquid silicones and yet it unexpectedly produces quality foam.
This invention offers a number of other benefits to the user which are also desirable objectives. The drug delivery system in the form of foam facilitates a novel, yet efficient mode of topical drug delivery system. It also facilitates continuous product output thereby adding ease of application. When dispensed in small quantity, the drug delivery system in the form of a foam can also cover a larger surface area of application while also facilitating better product application in areas where conventional topical products cannot be as effective. The drug delivery system in the form of foam also facilitates the use of a lower dosage which can minimize adverse reactions. The other crucial benefit is that this foam form of delivery system is devoid of any contact with air, light, or any other form of contamination as this is a completely sealed system throughout the life of the product.
Thus, light and oxidation prone topical actives can be preserved effectively in the aerosol system. The anhydrous system of the carrier further extends the preservation of topical actives that are otherwise easily degraded by presence of a water base.
Accordingly, it is a primary object of the present invention to prepare a topical application or pharmaceutical composition which is of widespread applicability (i.e. useful with many drug actives) and which is at the same time perceived by the user as pharmaceutically elegant.
Another objective of the present invention is to achieve the primary object with a composition especially adapted for lipophilic compounds and which can provide effective delivery in the form of a foam.
A yet further objective is to provide a method of preparation of a topical application or pharmaceutical composition in the form of a foam that achieves each of the above objectives or attributes.
The method and manner of achieving each of the above objectives as well as other objectives of the invention, will become apparent from the following detailed description of the invention.
SUMMARY OF THE INVENTION
A topical pharmaceutical aerosol foam composition containing a lipophilic compound, a liquid silicone, a foaming agent, a propellant and a topical pharmaceutical active. The composition may also contain rheology modifiers that serve as foam stabilizers. The composition exhibits excellent emollient and rub-in characteristics. The composition when expelled from an aerosolized container produces surprisingly good.
quality foam from a composition consisting of large quantities of liquid silicones, which are normally inherently de-foamers.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
For describing the compositions certain definitional terms are appropriate.
"Pharmaceutically elegant" has been previously defined. The "pharmaceutical composition" as used throughout the present specification and the accompanying claims is to be understood as defining the compositions of which the individual components or ingredients are themselves pharmaceutically acceptable, e.g. that is they are topically acceptable actives. Put another way, they are either FDA approved or on the GRAS safe list. The term "topically active pharmaceutical" is intended to be non-limiting and includes those pharmaceutical active agents that are commonly applied topically such as waterproofing agents, skinbarrier agents, skin conditioning agents, solvents, bio-adhesives, acne actives, analgesics, anesthetics, anorectics, antihistamines, anti-inflammatory agents, antibiotics, antifungals, antivirals, antimicrobials, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatics, antiseborrheics, astringents, biologically active proteins and peptides, burn actives, cauterizing agents, depigmenting agents, diaper rash agents, enzymes, hair growth actives, hemostatics, keratolytics, canker sore actives, cold sore actives, photosensitizing actives, steroids, sunburn actives, sunscreens, vaginal actives, wart actives, wound care actives; and retinol, retinoic acid and retinoic acid derivatives.
These may also include prescription and over-the-counter (OTC) drug products.
It is understood that this list is by way of example and not a limitation with respect to the active.
The term "pharmaceutically-effective amount of a topically active pharmaceutical" is intended to mean that a sufficient amount of the topically active pharmaceutical is present in the composition to perform its intended purpose.
In the present invention, there are five essential ingredients. The first is a lipophilic compound or combinations of lipophilic compounds selected from the group, including but not limited to, petrolatum, mineral oil, vegetable oils, fatty acids, glycerides, medium chain triglycerides, or combinations thereof. The amount of lipophilic compound or combinations of lipophilic compounds is from about 1% to about 80% by weight of the total composition. Preferably, the amount of lipophilic compound or combinations of lipophilic compounds is from about 5% to about 65% by weight of the total composition.
Various grades of Petrolatum exist, one of which is manufactured by Crompton under the grade Perfecta; a source of the medium chain triglycerides is Neobee 1053 manufactured by Stepan; and a source of mineral oil is Kaydol White Mineral Oil manufactured by Crompton. An example of a medium chain triglyceride is caprylic/capric triglyceride.
The second essential ingredient is a liquid silicone or a combination of liquid silicones which are used to overcome the oily/greasy feel of the lipophilic compound during application to the skin and to provide good skin feel and rub in characteristics. The liquid silicone is selected from the group consisting of silicones, silicone derivatives, cyclomethicone, or combinations thereof. The amount of liquid silicone or combinations of liquid silicones is from about 1% to about 80% by weight of the total composition.
Preferably, the amount of liquid silicone or combinations of liquid silicones is from about 5% to about 35% by weight of the total composition. Preferably, the liquid silicone used is Cyclomethicone, one source of which is ST-Cyclomethicone 5-NF manufactured by Dow Corning.
The third essential ingredient is a foaming agent, which is capable of foaming a product containing the above referenced liquid silicone. The foaming agent used is selected from the group consisting of mono, di, tri esters of Sorbitol and fatty acids. The amount of foaming agent used is from about 0.5% to about 25% by weight of the total composition. Preferably, the amount of the foaming agent used is from about 3%
to about 7% by weight of the total composition. The preferred foaming agent used is Sorbitan Monooleate one source of which is Span 80V Pharma manufactured by Uniqema.
The fourth essential ingredient is a pharmaceutically-effective amount of a topically active pharmaceutical, or in other words, the drug active. Suitable drug active categories have been previously listed. Some of these in specific can be Hydrocortisone, Zinc Oxide, Titanium Dioxide, Retinol, Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate, Tretinoin, Salicylic Acid, Lidocaine, Tetracaine, Sodium"Sulfacetamide, Boric acid, Ketoconazole, Tolnaftate, Tretinoin, Anthralin, Zinc Pyrithione, Menthol, Thymol, Desonide, Methyl Salicylate, Camphor, Clobetasol Propionate, Aluminum Sulfate, Trypsin, etc. Generally, the drug actives are present in amount from about 0.01% to about 40%
weight of the total composition.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
For describing the compositions certain definitional terms are appropriate.
"Pharmaceutically elegant" has been previously defined. The "pharmaceutical composition" as used throughout the present specification and the accompanying claims is to be understood as defining the compositions of which the individual components or ingredients are themselves pharmaceutically acceptable, e.g. that is they are topically acceptable actives. Put another way, they are either FDA approved or on the GRAS safe list. The term "topically active pharmaceutical" is intended to be non-limiting and includes those pharmaceutical active agents that are commonly applied topically such as waterproofing agents, skinbarrier agents, skin conditioning agents, solvents, bio-adhesives, acne actives, analgesics, anesthetics, anorectics, antihistamines, anti-inflammatory agents, antibiotics, antifungals, antivirals, antimicrobials, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatics, antiseborrheics, astringents, biologically active proteins and peptides, burn actives, cauterizing agents, depigmenting agents, diaper rash agents, enzymes, hair growth actives, hemostatics, keratolytics, canker sore actives, cold sore actives, photosensitizing actives, steroids, sunburn actives, sunscreens, vaginal actives, wart actives, wound care actives; and retinol, retinoic acid and retinoic acid derivatives.
These may also include prescription and over-the-counter (OTC) drug products.
It is understood that this list is by way of example and not a limitation with respect to the active.
The term "pharmaceutically-effective amount of a topically active pharmaceutical" is intended to mean that a sufficient amount of the topically active pharmaceutical is present in the composition to perform its intended purpose.
In the present invention, there are five essential ingredients. The first is a lipophilic compound or combinations of lipophilic compounds selected from the group, including but not limited to, petrolatum, mineral oil, vegetable oils, fatty acids, glycerides, medium chain triglycerides, or combinations thereof. The amount of lipophilic compound or combinations of lipophilic compounds is from about 1% to about 80% by weight of the total composition. Preferably, the amount of lipophilic compound or combinations of lipophilic compounds is from about 5% to about 65% by weight of the total composition.
Various grades of Petrolatum exist, one of which is manufactured by Crompton under the grade Perfecta; a source of the medium chain triglycerides is Neobee 1053 manufactured by Stepan; and a source of mineral oil is Kaydol White Mineral Oil manufactured by Crompton. An example of a medium chain triglyceride is caprylic/capric triglyceride.
The second essential ingredient is a liquid silicone or a combination of liquid silicones which are used to overcome the oily/greasy feel of the lipophilic compound during application to the skin and to provide good skin feel and rub in characteristics. The liquid silicone is selected from the group consisting of silicones, silicone derivatives, cyclomethicone, or combinations thereof. The amount of liquid silicone or combinations of liquid silicones is from about 1% to about 80% by weight of the total composition.
Preferably, the amount of liquid silicone or combinations of liquid silicones is from about 5% to about 35% by weight of the total composition. Preferably, the liquid silicone used is Cyclomethicone, one source of which is ST-Cyclomethicone 5-NF manufactured by Dow Corning.
The third essential ingredient is a foaming agent, which is capable of foaming a product containing the above referenced liquid silicone. The foaming agent used is selected from the group consisting of mono, di, tri esters of Sorbitol and fatty acids. The amount of foaming agent used is from about 0.5% to about 25% by weight of the total composition. Preferably, the amount of the foaming agent used is from about 3%
to about 7% by weight of the total composition. The preferred foaming agent used is Sorbitan Monooleate one source of which is Span 80V Pharma manufactured by Uniqema.
The fourth essential ingredient is a pharmaceutically-effective amount of a topically active pharmaceutical, or in other words, the drug active. Suitable drug active categories have been previously listed. Some of these in specific can be Hydrocortisone, Zinc Oxide, Titanium Dioxide, Retinol, Bacitracin Zinc, Polymyxin B Sulfate, Neomycin Sulfate, Tretinoin, Salicylic Acid, Lidocaine, Tetracaine, Sodium"Sulfacetamide, Boric acid, Ketoconazole, Tolnaftate, Tretinoin, Anthralin, Zinc Pyrithione, Menthol, Thymol, Desonide, Methyl Salicylate, Camphor, Clobetasol Propionate, Aluminum Sulfate, Trypsin, etc. Generally, the drug actives are present in amount from about 0.01% to about 40%
weight of the total composition.
And finally, the fifth essential ingredient is a propellant, which is used to expel the composition from the aerosol container. The propellant is selected from the group consisting of hydrocarbons like Butane, Propane, Pentane, Isopentane, Isobutane or Mixtures thereof supplied by Aeropres under the Trade name of A-70 and hydroflourocarbons like DuPont's Dyme1236fa, which is 1,1,1,3,3,3 hexafluoropropane or Dymel 227ea/P which is 1,1,1,2,3,3,3 heptafluoropropane or the propellant of choice here being Dymel 134a/P which is 1,1,1,2 Tetrafluoroethane. The amount of propellant used ranges from about 1% to about 30% by weight of the total composition.
Preferably, the amount of propellant used ranges from about 5% to 20% by weight of the total composition.
The composition may further contain rheology modifiers, which are capable of sustaining the foam. The rheology modifier if used may be selected from the group consisting of polyoxyl 40 hydrogenated castor oil, beeswax, paraffin wax, or combinations thereof. Sources of the Polyoxyl 40 Hydrogenated Castor oil are Lipocol HCO 40 manufactured by Lipo Chemicals or Cremophor RH-40 manufactured by BASF. A
source of the Beeswax is White Wax SP422P NF manufactured by Strahl and Pitsch, and a source of the Paraffin wax is SP-674 manufactured by Strahl and Pitsch. The amount of rheology modifier used in the composition ranges from about 0.05% to about 15% by weight of the total composition. Preferably, the amount of rheology modifier used in the composition ranges from about 1% to about 5% by weight of the total composition.
Critical to the invention, therefore, is the combination of all five of the essential ingredients listed above to create the desired pharmaceutically elegant foam.
When these are used in combination with the surfactant system herein specified, the dispensed foam is stabilized and of good quality in the presence of what would otherwise be defoamer, i.e., the silicones.
The following examples are offered to further illustrate, but not necessarily limit both the process and the composition of the present invention.
Preferably, the amount of propellant used ranges from about 5% to 20% by weight of the total composition.
The composition may further contain rheology modifiers, which are capable of sustaining the foam. The rheology modifier if used may be selected from the group consisting of polyoxyl 40 hydrogenated castor oil, beeswax, paraffin wax, or combinations thereof. Sources of the Polyoxyl 40 Hydrogenated Castor oil are Lipocol HCO 40 manufactured by Lipo Chemicals or Cremophor RH-40 manufactured by BASF. A
source of the Beeswax is White Wax SP422P NF manufactured by Strahl and Pitsch, and a source of the Paraffin wax is SP-674 manufactured by Strahl and Pitsch. The amount of rheology modifier used in the composition ranges from about 0.05% to about 15% by weight of the total composition. Preferably, the amount of rheology modifier used in the composition ranges from about 1% to about 5% by weight of the total composition.
Critical to the invention, therefore, is the combination of all five of the essential ingredients listed above to create the desired pharmaceutically elegant foam.
When these are used in combination with the surfactant system herein specified, the dispensed foam is stabilized and of good quality in the presence of what would otherwise be defoamer, i.e., the silicones.
The following examples are offered to further illustrate, but not necessarily limit both the process and the composition of the present invention.
Example 1: Vehicle In egr dient %w/w Caprylic/Capric Triglyceride 20.00 Mineral Oil 8.00 Cyclomethicone 31.25 Sorbitan Oleate 5.00 Polyoxyl 40 Hydrogenated Castor Oil 4.00 Petrolatum 30.00 Beeswax 0.75 Hydrogenated Castor Oil 1.00 All ingredients are weighed in a vessel and it is heated to 70-75 C, and mixed well until uniform. It is then cooled to ambient and pressurized in an aerosol can with Hydroflourocarbon in the ratio: Base: 85%, Propellant: 15%.
Example 2: Diaper Rash Ingredient %w/w Caprylic/Capric Triglyceride 25.50 Mineral Oil 8.00 Cyclomethicone 20.00 Beeswax 1.50 Sorbitan Monooleate 4.50 Hydrogenated Castor Oil 0.50 Zinc Oxide 40.00 All ingredients are weighed in a vessel except the Zinc Oxide and it is heated to 70-75 C, and mixed well until uniform. It is then cooled to 45 C and gradually added is dispersed Zinc Oxide, thus avoiding any lump formation. It is then cooled to ambient and pressurized in an aluminum aerosol can with Hydroflourocarbon in the ratio:
Base: 80%, Propellant: 20%.
Example 3: Antipuritic Ingredient %w/w Caprylic/Capric Triglyceride 24.50 Mineral Oil 10.00 Cyclomethicone 32.00 Beeswax 1.50 Sorbitan Monooleate 6.00 Petrolatum 25.00 Hydrocortisone 1.00 All ingredients are weighed in a vessel except Hydrocortisone and it is heated to 70-75 C and mixed well until uniform. It is then cooled to 35 C and then gradually added and dispersed is the Hydrocortisone. It is then cooled to ambient and pressurized in an aluminum aerosol can with Hydrofluorocarbon in the ratio: Base: 90%, Propellant: 10%.
For each of examples 1-3 the product when tested for foaming characteristics produces an elegant skin feel product with good and stable foam characteristics and the delivery was deemed excellent.
From the above examples, it can be seen that the invention accomplishes at least all of its stated objectives.
Example 2: Diaper Rash Ingredient %w/w Caprylic/Capric Triglyceride 25.50 Mineral Oil 8.00 Cyclomethicone 20.00 Beeswax 1.50 Sorbitan Monooleate 4.50 Hydrogenated Castor Oil 0.50 Zinc Oxide 40.00 All ingredients are weighed in a vessel except the Zinc Oxide and it is heated to 70-75 C, and mixed well until uniform. It is then cooled to 45 C and gradually added is dispersed Zinc Oxide, thus avoiding any lump formation. It is then cooled to ambient and pressurized in an aluminum aerosol can with Hydroflourocarbon in the ratio:
Base: 80%, Propellant: 20%.
Example 3: Antipuritic Ingredient %w/w Caprylic/Capric Triglyceride 24.50 Mineral Oil 10.00 Cyclomethicone 32.00 Beeswax 1.50 Sorbitan Monooleate 6.00 Petrolatum 25.00 Hydrocortisone 1.00 All ingredients are weighed in a vessel except Hydrocortisone and it is heated to 70-75 C and mixed well until uniform. It is then cooled to 35 C and then gradually added and dispersed is the Hydrocortisone. It is then cooled to ambient and pressurized in an aluminum aerosol can with Hydrofluorocarbon in the ratio: Base: 90%, Propellant: 10%.
For each of examples 1-3 the product when tested for foaming characteristics produces an elegant skin feel product with good and stable foam characteristics and the delivery was deemed excellent.
From the above examples, it can be seen that the invention accomplishes at least all of its stated objectives.
Claims (19)
1. An anhydrous, topical pharmaceutical aerosol foam composition, comprising in pharmaceutically-elegant and effective amounts: a lipophilic compound or combinations of lipophilic compounds selected from the group consisting of petrolatum, mineral oil, vegetable oils, fatty acids, glycerides, medium chain triglycerides; a liquid silicone or combinations of liquid silicones; a foaming agent; a topically active pharmaceutical; and a propellant.
2. The composition of claim 1 wherein the lipophilic compound is mineral oil.
3. The composition of claim 1 wherein the lipophilic compound is a medium chain triglyceride.
4. The composition of claim 1 wherein the lipophilic compound is a mixture of petrolatum, mineral oil and a medium chain triglyceride.
5. The composition of claim 1 wherein the liquid silicone is selected from the group consisting of silicones and silicone derivatives or combinations thereof.
6. The composition of claim 1 wherein the foaming agent is selected from the group consisting of mono, di, tri esters of sorbitol, fatty acids, and combinations thereof.
7. The composition of claim 1 wherein the esters of sorbitol are selected from the group consisting of: sorbitan caprylate, sorbitan diisostearate, sorbitan dioleate, sorbitan isostearate, sorbitan laurate, sorbitan monooleate, sorbitan trioleate, sorbitan sesquioleate, and combinations thereof.
8. The composition of claim 7 wherein the foaming agent is sorbitan monooleate.
9. The composition of claim 8 wherein the amount of sorbitan monooleate ranges from about 0.5% to about 25% by weight of the total anhydrous, topical pharmaceutical aerosol foam composition.
10. The composition of claim 1 further comprising a rheology modifier.
11. The composition of claim 10 wherein the rheology modifier is selected from the group consisting of polyoxyl 40 hydrogenated castor oil, beeswax, paraffin wax, and combinations thereof;
12. The composition of claim 1 wherein the topically active pharmaceutical is selected from the group consisting of acne actives, analgesics, anesthetics, anorectics, antihistamines, anti-inflammatory agents, antibiotics, antifungals, antivirals, antimicrobials, scabicides, pediculicides, antineoplastics, antiperspirants, antipruritics, antipsoriatics, antiseborrheics, astringents, biologically active proteins and peptides, burn actives, cauterizing agents, depigmenting agents, diaper rash agents, enzymes, hair growth actives, hemostatics, keratolytics, canker sore actives, cold sore actives, dental actives, saliva actives, photosensitizing actives, skin protectant/barrier agents, steroids, sunburn actives, sunscreens, vaginal actives, wart actives, wound care actives; and retinol, retinoic acid and retinoic acid derivatives.
13. The composition of claim 1 wherein the propellant is a hydrocarbon.
14. The composition of claim 1 wherein the propellant is a hydroflourocarbon.
15. The composition of claim 5 wherein the liquid silicone is cyclomethicone.
16. The composition of claim 1 wherein the amount of liquid silicone or combinations of liquid silicones range from about 1% to about 80% by weight of the total anhydrous, topical pharmaceutical aerosol foam composition.
17. The composition of claim 13 wherein the hydrocarbon is selected from the group consisting of butane, isomers of butane, propane, isomers of propane, pentane, isomers of pentane, and combinations thereof.
18. The composition of claim 14 wherein the hydrofluorocarbon is selected from the group consisting of 1,1,1,2 tetrafluoroethane and 1,1,1,2,3,3,3 heptafluoropropane.
19. The composition of claim 1 wherein the amount of lipophilic compound or combinations of lipophilic compounds range from about 1% to about 80% by weight of the total anhydrous, topical pharmaceutical aerosol foam composition.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/875,470 US8211449B2 (en) | 2004-06-24 | 2004-06-24 | Pharmaceutically elegant, topical anhydrous aerosol foam |
US10/875,470 | 2004-06-24 | ||
PCT/US2005/021229 WO2006031271A2 (en) | 2004-06-24 | 2005-06-16 | Pharmaceutically elegant, topical anhydrous aerosol foam |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2570450A1 true CA2570450A1 (en) | 2006-03-23 |
CA2570450C CA2570450C (en) | 2013-02-19 |
Family
ID=35505989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2570450A Expired - Fee Related CA2570450C (en) | 2004-06-24 | 2005-06-16 | Pharmaceutically elegant, topical anhydrous aerosol foam |
Country Status (9)
Country | Link |
---|---|
US (1) | US8211449B2 (en) |
EP (1) | EP1765286B1 (en) |
JP (1) | JP2008504259A (en) |
KR (1) | KR20070050040A (en) |
CN (1) | CN101014315A (en) |
AU (1) | AU2005285441B2 (en) |
BR (1) | BRPI0512574B8 (en) |
CA (1) | CA2570450C (en) |
WO (1) | WO2006031271A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
EP1556009B2 (en) | 2002-10-25 | 2021-07-21 | Foamix Pharmaceuticals Ltd. | Cosmetic and pharmaceutical foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US20080031907A1 (en) * | 2002-10-25 | 2008-02-07 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
WO2007022090A2 (en) * | 2005-08-13 | 2007-02-22 | Collegium Pharmaceutical, Inc. | Topical delivery with a carrier fluid |
US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
JP2010515766A (en) * | 2007-01-16 | 2010-05-13 | オイスターシェル エヌ.ブイ. | Effervescent composition and use thereof for killing arthropods |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013008A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8454942B1 (en) | 2011-11-29 | 2013-06-04 | L'oreal | Cosmetic oil mousse composition |
CN103552188B (en) * | 2013-10-25 | 2016-01-20 | 佳木斯大学 | Oral medical material release agent and preparation method thereof |
KR101741981B1 (en) * | 2015-04-22 | 2017-06-01 | 코스맥스 주식회사 | Aerosol cosmetic composition of leave on type |
WO2017137905A1 (en) | 2016-02-09 | 2017-08-17 | Coast Southwest, Inc. | Foam boosting saccharide blend |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
DE102016223502A1 (en) * | 2016-11-28 | 2018-05-30 | Beiersdorf Ag | UV-filter-containing, cosmetic foam comprising an emulsion containing sodium cetearyl sulfate and glyceryl monostearate |
EP4003302A1 (en) * | 2019-07-31 | 2022-06-01 | Journey Medical Corporation | Compositions and methods and uses thereof |
WO2023120699A1 (en) * | 2021-12-24 | 2023-06-29 | 花王株式会社 | Frothing method |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA975500A (en) | 1969-02-06 | 1975-09-30 | Joseph G. Spitzer | Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same, and process |
US3770648A (en) | 1971-07-12 | 1973-11-06 | Bristol Myers Co | Anhydrous aerosol foam |
US3929985A (en) | 1974-01-18 | 1975-12-30 | Richardson Merrell Inc | Anhydrous candicidin foam compositions |
US3949096A (en) * | 1974-07-31 | 1976-04-06 | Scm Corporation | Spray drying process for encapsulation of condiment particles |
LU83020A1 (en) | 1980-12-19 | 1982-07-07 | Oreal | OIL COMPOSITION FOR THE TREATMENT OF KERATINIC MATERIALS AND THE SKIN |
US4574052A (en) | 1984-05-31 | 1986-03-04 | Richardson-Vicks Inc. | Crackling aerosol foam |
US4639367A (en) | 1985-03-18 | 1987-01-27 | Product Resources International, Inc. | Aerosol foam |
US4752465A (en) * | 1985-09-20 | 1988-06-21 | Product Resources International, Inc. | Aerosol foam |
US4889709A (en) | 1985-03-18 | 1989-12-26 | Product Resources International, Inc. | Aerosol foam with adsorbate and container containing same |
US5250289A (en) | 1987-07-24 | 1993-10-05 | The Boots Company Plc | Sunscreen compositions |
US4981677A (en) * | 1987-09-23 | 1991-01-01 | L'oreal | Petrolatum-containing aerosol foam concentrate |
US5262407A (en) | 1988-12-16 | 1993-11-16 | L'oreal | Use of salicylic derivatives for the treatment of skin aging |
US5322683A (en) | 1989-05-01 | 1994-06-21 | Leonard Mackles | Anhydrous aerosol foam |
SE9000485D0 (en) | 1990-02-09 | 1990-02-09 | Pharmacia Ab | FOAMABLE COMPOSITION FOR PHARMACEUTICAL USE, USE THEREOF AND METHOD OF TREATMENT |
US5077053A (en) * | 1990-02-12 | 1991-12-31 | Warner-Lambert Company | Zein as a moisture barrier for sugarless edible compositions and method for preparing same |
FR2668927B1 (en) * | 1990-11-09 | 1993-01-08 | Oreal | COSMETIC ANHYDROUS COMPOSITION IN AEROSOL FORM FOR THE FORMATION OF A FOAM. |
FR2673179B1 (en) | 1991-02-21 | 1993-06-11 | Oreal | CERAMIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS IN COSMETICS AND DERMOPHARMACY. |
US5409706A (en) | 1992-05-04 | 1995-04-25 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters |
US5254334A (en) * | 1992-05-04 | 1993-10-19 | Imaginative Research Associates, Inc. | Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters |
US5357636A (en) | 1992-06-30 | 1994-10-25 | Dresdner Jr Karl P | Flexible protective medical gloves and methods for their use |
US5296021A (en) * | 1992-10-28 | 1994-03-22 | Creative Products Inc. Of Rossville | Aerosol-dispensable foodstuffs parting composition |
GB2275419B (en) | 1993-02-27 | 1996-11-13 | Procter & Gamble | Silicone-based oil-in-water cosmetic compositions |
US5616746A (en) | 1993-04-15 | 1997-04-01 | L'oreal | Use in cosmetics of lipophilic derivatives of amino deoxyalditols, cosmetic compositions containing them, and novel alkyl carbamates |
FR2711138B1 (en) | 1993-10-12 | 1995-11-24 | Oreal | Ceramides, their preparation process and their applications in cosmetics and dermopharmacy. |
US5679324A (en) | 1994-07-08 | 1997-10-21 | The Procter & Gamble Co. | Aerosol foamable fragrance composition |
GB9414699D0 (en) * | 1994-07-21 | 1994-09-07 | Slagel David | Aqueous foamable composition |
US6013269A (en) | 1994-10-12 | 2000-01-11 | The Procter & Gamble Company | Cosmetic make-up compositions |
GB9420535D0 (en) | 1994-10-12 | 1994-11-30 | Procter & Gamble | Cosmetic make-up compositions |
WO1996019921A1 (en) | 1994-12-23 | 1996-07-04 | Commonwealth Scientific And Industrial Research Organisation | Iodine biocidal material |
EP0738510A3 (en) | 1995-04-20 | 2005-12-21 | L'oreal | Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties. |
CA2224798A1 (en) | 1995-06-22 | 1997-01-09 | Matthew T. Scholz | Stable hydroalcoholic compositions |
FR2737115B1 (en) | 1995-07-25 | 1997-08-22 | Oreal | STABLE COMPOSITION CONTAINING AN ENZYME |
US5716611A (en) | 1996-01-02 | 1998-02-10 | Euro-Celtique, S.A. | Emollient antimicrobial formulations containing povidone iodine |
DE19631221C2 (en) | 1996-08-02 | 1999-07-01 | Beiersdorf Ag | Foam-form sunscreen preparations containing water-soluble sunscreen filter substances and surface-active substances |
US5997854A (en) | 1996-12-10 | 1999-12-07 | Henkel Corporation | Conditioning shampoo formulation |
SE9703226D0 (en) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
JP4769357B2 (en) * | 1998-01-30 | 2011-09-07 | ザ フォルジャーズ コーヒー カンパニー | Beverages with improved texture and flavor at low doses of solids |
US6121210A (en) | 1998-03-12 | 2000-09-19 | Dap Products Inc. | Foamable silicone oil compositions and methods of use thereof |
DE19835239A1 (en) | 1998-08-04 | 2000-02-24 | Johnson & Johnson Gmbh | Foaming oil preparation and its use |
GB9817817D0 (en) | 1998-08-14 | 1998-10-14 | Unilever Plc | Cosmetic composition |
IL129102A0 (en) | 1999-03-22 | 2000-02-17 | J P M E D Ltd | An emulsion |
US6524594B1 (en) | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
NL1012419C2 (en) | 1999-06-23 | 2000-12-28 | Airspray Nv | Aerosol for dispensing a liquid. |
US6627178B1 (en) | 1999-07-30 | 2003-09-30 | Garret D. Cawthon | Methods, compositions and systems for the prevention and treatment of diaper rash |
US6287580B1 (en) | 1999-08-13 | 2001-09-11 | Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. | Cosmetic compositions with self-warming component |
AU2001234509A1 (en) | 2000-01-20 | 2001-07-31 | The Procter And Gamble Company | Antimicrobial compositions |
US6503517B1 (en) | 2000-01-28 | 2003-01-07 | Conopco, Inc. | Cosmetic compositions with menthol |
US20030185877A1 (en) * | 2000-03-17 | 2003-10-02 | Roland Betz | Method of producing oily suspensions of water-soluble vitamins |
EP1272144A4 (en) | 2000-03-27 | 2006-04-26 | Schott Ag | New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same |
AU2001248715B2 (en) | 2000-05-08 | 2005-10-13 | Pfizer Products Inc. | Skin protectant spray compositions |
US20030180337A1 (en) | 2000-06-06 | 2003-09-25 | Harald Streicher | Use of an (r)-enantiomer of lipoic acid in cosmetics and dermatologicals |
US20020164381A1 (en) | 2000-06-30 | 2002-11-07 | Medicis Pharmaceutical Corporation | Mitocidal compositions and methods |
JP3481599B2 (en) * | 2000-07-14 | 2003-12-22 | 京都電機器株式会社 | Linear lighting device |
DE10036655A1 (en) | 2000-07-26 | 2002-02-07 | Basf Ag | Cosmetic or dermatological preparations to prevent skin damage from peroxides |
DE10041220A1 (en) | 2000-08-22 | 2002-03-07 | Basf Ag | Skin cosmetic formulations |
US20040018228A1 (en) | 2000-11-06 | 2004-01-29 | Afmedica, Inc. | Compositions and methods for reducing scar tissue formation |
DE10058384B4 (en) | 2000-11-24 | 2004-12-16 | Wella Aktiengesellschaft | Cosmetic or dermatological agent in the form of a creamy permanent foam or a stably foamed cream, its use and method for producing the agent |
US6555099B2 (en) | 2000-12-12 | 2003-04-29 | The Procter & Gamble Company | Single-phase antiperspirant compositions containing solubilized antiperspirant active and volatile silicone |
US6696067B2 (en) | 2001-04-12 | 2004-02-24 | Ondeo Nalco Company | Cosmetic compositions containing dispersion polymers |
US6375938B1 (en) | 2001-04-26 | 2002-04-23 | The Gillette Company | Antiperspirant and deodorant compositions containing a low molecular weight polyethylene gellant |
US6485715B1 (en) | 2001-05-23 | 2002-11-26 | The Proctor & Gamble Company | Stable pressurized antiperspirant compositions containing dimethylether propellant and a low polarity solvent |
DE10138495B4 (en) | 2001-08-04 | 2004-11-11 | Beiersdorf Ag | Foaming preparations and their use |
US6479060B1 (en) | 2001-09-04 | 2002-11-12 | Healthpoint, Ltd. | Elegant hydrogenated castor oil ointments |
WO2003035015A1 (en) | 2001-10-26 | 2003-05-01 | Taiyo Kagaku Co., Ltd. | Composition for oily foamable aerosol |
DE10155542A1 (en) | 2001-11-12 | 2003-05-22 | Basf Ag | Cosmetic or dermatological sunscreen preparation |
CA2471400A1 (en) | 2001-12-20 | 2003-07-03 | Femmepharma, Inc. | Vaginal delivery of drugs |
US6846940B2 (en) | 2002-01-22 | 2005-01-25 | L'oreal | Ceramides, compositions thereof and methods of use thereof |
ATE334654T1 (en) | 2002-06-03 | 2006-08-15 | Ciba Sc Holding Ag | COMPOSITIONS PROTECTIVE FROM UV RAYS |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US7575739B2 (en) * | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
FR2862540B1 (en) | 2003-11-21 | 2007-03-30 | Galderma Res & Dev | SPRAY COMPOSITION COMPRISING A PHARMACEUTICAL ACTIVE, AT LEAST ONE VOLATILE SILICONE AND A NON-VOLATILE NON-POLAR PHASE |
WO2005097068A1 (en) | 2004-04-08 | 2005-10-20 | Novartis Ag | Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
US20050255063A1 (en) * | 2004-05-14 | 2005-11-17 | Fenwick-Le Vine Jan L | Candy cosmetics |
US20050281806A1 (en) | 2004-06-16 | 2005-12-22 | Collegium Pharmaceutical, Inc., Delaware | Compositions for topical enzymatic debridement |
FR2871696B1 (en) | 2004-06-17 | 2006-11-10 | Galderma Sa | TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS |
-
2004
- 2004-06-24 US US10/875,470 patent/US8211449B2/en active Active
-
2005
- 2005-06-16 JP JP2007518125A patent/JP2008504259A/en not_active Withdrawn
- 2005-06-16 CA CA2570450A patent/CA2570450C/en not_active Expired - Fee Related
- 2005-06-16 KR KR1020077001681A patent/KR20070050040A/en not_active Application Discontinuation
- 2005-06-16 CN CNA2005800210969A patent/CN101014315A/en active Pending
- 2005-06-16 WO PCT/US2005/021229 patent/WO2006031271A2/en active Application Filing
- 2005-06-16 AU AU2005285441A patent/AU2005285441B2/en not_active Ceased
- 2005-06-16 EP EP05821068A patent/EP1765286B1/en not_active Not-in-force
- 2005-06-16 BR BRPI0512574A patent/BRPI0512574B8/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2005285441A1 (en) | 2006-03-23 |
EP1765286B1 (en) | 2012-09-05 |
BRPI0512574A (en) | 2008-03-25 |
AU2005285441B2 (en) | 2010-04-29 |
BRPI0512574B1 (en) | 2018-06-26 |
BRPI0512574B8 (en) | 2021-05-25 |
CA2570450C (en) | 2013-02-19 |
CN101014315A (en) | 2007-08-08 |
EP1765286A2 (en) | 2007-03-28 |
JP2008504259A (en) | 2008-02-14 |
US20050287081A1 (en) | 2005-12-29 |
US8211449B2 (en) | 2012-07-03 |
WO2006031271A3 (en) | 2006-06-01 |
WO2006031271A2 (en) | 2006-03-23 |
KR20070050040A (en) | 2007-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2570450C (en) | Pharmaceutically elegant, topical anhydrous aerosol foam | |
US6423323B2 (en) | Foam skin cream, uses of the foam skin protection cream and a process for its preparation | |
FI108277B (en) | Topical preparation containing a suspension of solid lipid particles | |
KR100381701B1 (en) | Topical ketoconazole emulsions | |
EP0691840B1 (en) | Silicone based skin care products | |
JPS621287B2 (en) | ||
EP0009404B1 (en) | Water-in-oil emulsions and process for preparing them | |
TW200914056A (en) | Stable high internal phase emulsions and compositions comprising the same | |
EP0330369A1 (en) | Skin conditioning composition | |
EP0016203A1 (en) | Anhydrous multi-purpose moisturizing composition | |
WO2001085156A1 (en) | Dermal compositions containing coenzyme q as the active ingredient | |
JP2003335629A (en) | Aerosol composition | |
US4062937A (en) | Insect bite relief preparation | |
JPS60228405A (en) | Skin treatment composition | |
EP0103910A1 (en) | Emollient-containing skin conditioning compositions | |
EP0103911A1 (en) | Emollient-containing topical pharmaceutical compositions | |
JP3851371B2 (en) | Non-aqueous oil-based ointment base and skin external ointment | |
EP0930066A2 (en) | Low tack lotion, gels and creams | |
US6124348A (en) | Vitamin C skin formulations | |
JPH0259507A (en) | Hair care composition | |
EP3866935B1 (en) | Method of reducing perspiration | |
JP3675637B2 (en) | Composition for external use | |
GB2327344A (en) | Pharmaceutical compositions containing phenytoin and either an azole anti-fungal/anti-bacterial agent and/or a silver salt for topical application | |
JPH0347249B2 (en) | ||
JP2001226258A (en) | Powdery aerosol composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20210616 |